Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Shonan iPark Looks to Woo Korean Firms by Partnering with Govt: Chief
iPark Institute is looking to set up an operating base in South Korea in two years and forge a partnership with the country’s government in a bid to attract local companies to a science park it manages, dubbed Shonan iPark,…
To read the full story
Related Article
- Shonan iPark to Drive Japan Approval of New Drugs from Korean Biotechs
February 26, 2025
- Shonan iPark Set for Expansion as It Looks to Establish Profile as Regenerative Medicine Hub
October 16, 2024
- Shonan iPark Commences Full-Fledged Operations in South Korea
July 16, 2024
- Shonan iPark Launches Local Post in South Korea
March 19, 2024
- iPark Institute Inks Collaboration Pact with South Korean Government
November 14, 2023
- iPark Institute Takes Over Shonan iPark Operations from Takeda to Boost Neutrality, Collaborations
April 14, 2023
- Takeda, Mitsubishi, IIF to Operate Shonan iPark under New Joint Firm
December 22, 2022
BUSINESS
- Takeda Says US Revamp “Not Simply Workforce Reduction” as 634 Roles Impacted
April 3, 2026
- New JCR President Confident in 100 Billion Yen Sales Target in 2030s
April 3, 2026
- Meiji Launches Rezurock in Thailand
April 3, 2026
- Mochida, LG Chem Ink Licensing Deal for Dienogest in South Korea, Thailand
April 3, 2026
- Lotte Invests in Rakuten Medical via Biopharma CVC
April 3, 2026
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…